Determination of the predictive value of FDG-PET-CT scans, blood proteins and blood cells for the prognosis for patients with lung cancer receiving concurrent chemo-radiation

Determination of the predictive value of FDG-PET-CT scans, blood proteins and blood cells for the prognosis for patients with lung cancer receiving concurrent chemo-radiation - FDG-PET-LUNG / TACIR

Status

Active, not recruiting

Phases

Phase 3

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON31446

Enrollment

Registered

2006-08-11

Start date

2006-05-01

Completion date

Unknown

Last updated

2024-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lungcancer

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Histological or cytological proven non-small cell or small cell lung cancer. Mixed histologies (NSCLC and SCLC) are allowed; UICC stage I-III (in case of small cell lung cancer: limited stage); WHO performance status 0-2; Less than 10 % weight loss the last 6 months; In case of previous chemotherapy, concurrent chemo-radiotherapy can start after a minimum of 21 days after the last chemotherapy course; No recent (

Exclusion criteria

Exclusion criteria: Not non-small cell or small cell histology, e.g. mesothelioma, lymphoma Malignant pleural or pericardial effusion History of prior chest radiotherapy Recent (

Design outcomes

Primary

Measure	Time frame
Tumour response, measured with FDG-PET-CT scans 3 months post-radiation, as a function of delta FDG uptafe the first week during radiotherapy	—

Secondary

Measure	Time frame
- Incidence of acute radiation-induced oesophagitis - Incidence of radiation-induced pulmonary toxicity 3 and 9 months post-radiotherapy	—

Countries

Netherlands

Outcome results